Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7810761 | PMC |
| http://dx.doi.org/10.1016/j.lrr.2021.100234 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Advancing Measurable Residual Disease Detection in Pediatric BCP-ALL: Insights from Novel Immunophenotypic Markers.
Int J Mol Sci
April 2025
Laboratory of Clinical Immunology, St. George University Hospital, Vasil Aprilov Str. 15A, 4002 Plovdiv, Bulgaria.
Measurable Residual Disease (MRD) assessment in pediatric acute lymphoblastic leukemia (ALL) is crucial for relapse prediction and treatment guidance. Multiparameter flow cytometry (MFC) enhances detection but faces limitations due to insufficient leukemia-associated immunophenotypes (LAIPs) and antigen modulation. This study explores new markers to improve MFC-based MRD detection in B-cell precursor ALL (BCP-ALL).
View Article and Find Full Text PDFFaster clinical decisions in B-cell acute lymphoblastic leukaemia: A single flow cytometric 12-colour tube improves diagnosis and minimal residual disease follow-up.
Br J Haematol
May 2024
Hématologie Biologique, CHU Clermont-Ferrand, Estaing, Clermont-Ferrand, France.
Assessing minimal residual disease (MRD) in B-cell precursor acute lymphoblastic leukaemia (BCP-ALL) is essential for adjusting therapeutic strategies and predicting relapse. Quantitative polymerase chain reaction (qPCR) is the gold standard for MRD. Alternatively, flow cytometry is a quicker and cost-effective method that typically uses leukaemia-associated immunophenotype (LAIP) or different-from-normal (DFN) approaches for MRD assessment.
View Article and Find Full Text PDFReinfusion of CD19 CAR T cells for relapse prevention and treatment in children with acute lymphoblastic leukemia.
Blood Adv
May 2024
Division of Oncology, Children's Hospital of Philadelphia, Philadelphia, PA.
Relapse after CD19-directed chimeric antigen receptor (CAR)-modified T cells remains a substantial challenge. Short CAR T-cell persistence contributes to relapse risk, necessitating novel approaches to prolong durability. CAR T-cell reinfusion (CARTr) represents a potential strategy to reduce the risk of or treat relapsed disease after initial CAR T-cell infusion (CARTi).
View Article and Find Full Text PDFDeciphering stage 0 hematogones by flow cytometry in follow-up bone marrow samples of pediatric B-Acute lymphoblastic leukemia cases: A potential mimicker of residual disease after anti CD19 therapy.
Cytometry B Clin Cytom
March 2024
Department of Pediatric Hematology, Oncology, Blood and Marrow Transplantation, Apollo Cancer Centre, Chennai, India.
CD19 is frequently targeted for immunotherapy in B cell malignancies, which may result in loss of CD19 expression in leukemic cells as an escape mechanism. Stage 0 hematogones (Hgs) are normal CD19-negative very early B cell precursors that can be potentially mistaken for CD19 negative residual leukemic cells by flow cytometry (FCM) in B cell acute lymphoblastic leukemia (BCP-ALL) cases treated with anti CD19 therapy. Our main objective was to characterize and study the incidence of stage 0 hematogones in follow-up bone marrow samples of pediatric BCP-ALL cases.
View Article and Find Full Text PDFComparison of Measurable Residual Disease in Pediatric B-Lymphoblastic Leukemia Using Multiparametric Flow Cytometry and Next-Generation Sequencing.
Ann Lab Med
July 2024
Department of Laboratory Medicine, Seoul National University College of Medicine, Seoul, Korea.
Article Synopsis
- * The study found a high concordance rate of 79.9% between the two testing methods, but the NGS method detected MRD more often than MFC, with some samples showing MRD only detected by NGS.
- * Hemodilution significantly affected the MFC results, and the analysis of hematogone percentages could help improve the assessment of sample quality in MRD evaluations.